Supplementary table 6a. Determinants of vaccine efficacy (incidence of
clinical malaria primary case definition, all episodes) full model during an 18month follow-up period in the 5-17 months age category (per-protocol
population)
Parameter
Treatment
Male versus female
Anti-CS study site average
Indoor Residual Spraying
Bednet use
Outpatient distance within 5 kilometers
Age 5-11 months versus 12-17 months
Low HAZ versus normal HAZ
Low WAZ versus normal WAZ
Moderate anemia
Incidence in controls
Treatment x Male versus female
Treatment x Anti-CS study site average
Treatment x Indoor Residual Spraying
Treatment x Bednet use
Treatment x Outpatient distance within 5 kilometers
Treatment x Age 5-11 months versus 12-17 months
Treatment x Low HAZ versus normal HAZ
Treatment x Low WAZ versus normal WAZ
Treatment x Moderate anemia
Treatment x Incidence in controls
Dispersion
Incident rate ratio
0.54
1.08
18.43
1.00
1.06
1.01
0.89
1.03
0.84
0.96
2.14
0.95
2.51
0.94
1.02
1.11
1.05
0.93
1.20
1.21
0.98
2.21
95% CI
LL
0.49
0.97
6.78
0.66
0.89
0.89
0.80
0.89
0.71
0.82
1.98
0.82
0.65
0.54
0.81
0.94
0.91
0.77
0.96
0.98
0.89
2.06
UL
0.59
1.21
50.07
1.51
1.26
1.14
1.00
1.18
1.00
1.14
2.30
1.10
9.74
1.65
1.27
1.30
1.22
1.12
1.49
1.50
1.08
2.38
p-value
<.001
0.170
<.001
0.994
0.531
0.884
0.056
0.739
0.045
0.652
<.001
0.520
0.182
0.838
0.896
0.228
0.513
0.455
0.106
0.071
0.655
_
The model included an intercept (not presented in the table above).
Incident rate ratios >1 corresponds to a factor associated with an increased risk of
malaria.
LL = Lower limit of the 95% confidence interval.
UL = Upper limit of the 95% confidence interval.
HAZ = Height-for-age Z-score.
WAZ = Weight-for-age Z-score.
P-value from negative binomial regression.
Page 1 of 4
Supplementary table 6b. Determinants of vaccine efficacy (incidence of
clinical malaria primary case definition, all episodes) final model during an
18-month follow-up period in the 5-17 months age category (per-protocol
population)
Parameter
Incident rate ratio
Treatment
Male versus female
Anti-CS study site average
Indoor Residual Spraying
Bednet use
Outpatient distance within 5 kilometers
Age 5-11 months versus 12-17 months
Low HAZ versus. normal HAZ
Low WAZ versus normal WAZ
Moderate anemia
Incidence in controls
Treatment x Moderate anemia
Dispersion
0.56
1.05
29.92
0.98
1.07
1.07
0.92
0.99
0.94
0.95
2.11
1.24
2.22
95% CI
LL
0.52
0.98
15.22
0.74
0.96
0.99
0.85
0.90
0.84
0.80
2.01
1.01
2.07
UL
0.60
1.13
58.80
1.29
1.19
1.16
0.99
1.08
1.04
1.11
2.21
1.52
2.39
p-value
<.001
0.168
<.001
0.864
0.246
0.097
0.021
0.742
0.228
0.502
<.001
0.041
_
The model included an intercept (not presented in the table above).
The full model includes all treatment-covariate interaction and the final model was
obtained by stepwise removal of non-significant (>0.05) interaction terms.
Incident rate ratios >1 corresponds to a factor associated with an increased risk of
malaria.
LL = Lower limit of the 95% confidence interval.
UL = Upper limit of the 95% confidence interval.
HAZ = Height-for-age Z-score.
WAZ = Weight-for-age Z-score.
P-value from negative binomial regression.
Page 2 of 4
Supplementary table 6c. Determinants of vaccine efficacy (incidence of
clinical malaria primary case definition, all episodes) full model during an 18month follow-up period in the 6-12 weeks age category (per-protocol
population)
Parameter
Incident rate ratio
Treatment
Male versus female
Anti-CS study site average
Indoor Residual Spraying
Bednet use
Outpatient distance within 5 kilometers
Age 6 weeks versus 7-12 weeks
Low HAZ versus normal HAZ
Low WAZ versus normal WAZ
Moderate anemia
Incidence in controls
Treatment x Male versus female
Treatment x Anti-CS study site average
Treatment x Indoor Residual Spraying
Treatment x Bednet use
Treatment x Outpatient distance within 5 kilometers
Treatment x Age 6 weeks versus 7-12 weeks
Treatment x Low HAZ versus normal HAZ
Treatment x Low WAZ versus normal WAZ
Treatment x Moderate anemia
Treatment x Incidence in controls
Dispersion
0.76
1.07
0.57
0.74
0.95
0.80
0.89
1.10
1.04
0.91
2.87
1.07
0.61
1.16
0.94
0.99
1.17
0.93
1.00
1.47
0.99
2.49
95% CI
LL
0.69
0.93
0.33
0.44
0.75
0.69
0.78
0.92
0.80
0.50
2.65
0.90
0.31
0.62
0.69
0.82
0.99
0.75
0.72
0.73
0.90
2.29
UL
0.84
1.23
1.00
1.26
1.22
0.94
1.02
1.31
1.35
1.65
3.10
1.28
1.21
2.18
1.27
1.20
1.39
1.16
1.40
2.99
1.10
2.74
p-value
<.001
0.336
0.051
0.271
0.717
0.005
0.103
0.305
0.765
0.750
<.001
0.420
0.154
0.636
0.675
0.931
0.070
0.521
0.981
0.284
0.902
_
The model included an intercept (not presented in the table above).
Incident rate ratios >1 corresponds to a factor associated with an increased risk of
malaria.
LL = Lower limit of the 95% confidence interval.
UL = Upper limit of the 95% confidence interval.
HAZ = Height-for-age Z-score.
WAZ = Weight-for-age Z-score.
P-value from negative binomial regression.
Page 3 of 4
Supplementary table 6d. Determinants of vaccine efficacy (incidence of
clinical malaria primary case definition, all episodes) final model during an
18-month follow-up period in the 6-12 weeks age category (per-protocol
population)
Parameter
Treatment
Male versus female
Anti-CS study site average
Indoor Residual Spraying
Bednet use
Outpatient distance within 5 kilometers
Age 6 weeks versus 7-12 weeks
Low HAZ versus normal HAZ
Low WAZ versus normal WAZ
Moderate anemia
Incidence in controls
Dispersion
Incident rate ratio
0.77
1.12
0.42
0.82
0.92
0.80
0.99
1.05
1.04
1.18
2.86
2.50
95% CI
LL
0.71
1.03
0.30
0.62
0.80
0.73
0.91
0.95
0.89
0.86
2.73
2.29
UL
0.84
1.22
0.58
1.09
1.07
0.88
1.07
1.17
1.22
1.63
2.99
2.75
p-value
<.001
0.007
<.001
0.174
0.284
<.001
0.768
0.365
0.605
0.301
<.001
_
The model included an intercept (not presented in the table above).
The full model includes all treatment-covariate interaction and the final model was
obtained by stepwise removal of non-significant (>0.05) interaction terms.
Incident rate ratios >1 corresponds to a factor associated with an increased risk of
malaria.
LL = Lower limit of the 95% confidence interval.
UL = Upper limit of the 95% confidence interval.
HAZ = Height-for-age Z-score.
WAZ = Weight-for-age Z-score.
P-value from negative binomial regression.
Page 4 of 4